WO2017162721A1 - Use of an aqueous composition for dissolving biomolecules from a tissue sample - Google Patents

Use of an aqueous composition for dissolving biomolecules from a tissue sample Download PDF

Info

Publication number
WO2017162721A1
WO2017162721A1 PCT/EP2017/056782 EP2017056782W WO2017162721A1 WO 2017162721 A1 WO2017162721 A1 WO 2017162721A1 EP 2017056782 W EP2017056782 W EP 2017056782W WO 2017162721 A1 WO2017162721 A1 WO 2017162721A1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
aqueous composition
sample
biomolecules
tissue sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2017/056782
Other languages
English (en)
French (fr)
Inventor
Johan De Meulemeester
Emmanuel Lemaire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allflex Europe SAS
Original Assignee
Allflex Europe SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allflex Europe SAS filed Critical Allflex Europe SAS
Priority to EP17711678.7A priority Critical patent/EP3417060B8/en
Priority to RU2018133641A priority patent/RU2745529C2/ru
Priority to CA3017679A priority patent/CA3017679A1/en
Priority to AU2017237464A priority patent/AU2017237464B2/en
Priority to BR112018069110-0A priority patent/BR112018069110B1/pt
Priority to CN201780031557.3A priority patent/CN109153991B/zh
Priority to JP2019501754A priority patent/JP2019512274A/ja
Priority to PL17711678T priority patent/PL3417060T3/pl
Priority to US16/086,908 priority patent/US20190100746A1/en
Publication of WO2017162721A1 publication Critical patent/WO2017162721A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10Preservation of living parts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]

Definitions

  • the present invention relates to the use of an aqueous composition for dissolving biomolecules from a tissue sample and to a method of using an aqueous composition for dissolving biomolecules from a tissue sample. Furthermore, the present invention relates to a system for preparing a tissue sample of an animal.
  • Tissue sampling tags are nowadays commonly used for tagging a livestock animal and at the same time withdrawing a sample from said animal. Such sample is then subsequently analyzed in the laboratory for the presence or absence of particular genetic traits, pathogens, or for genotyping said animal. Alternatively, the sample is simply kept and stored for tracing the origin of the animal from which said sample has been taken. Tissue samples may be obtained by using a tissue sampling tag or a tissue sampling unit, such as a biopsy needle. Tissue sampling tags are commonly known and are also commercially available, for example from the present applicant, Allflex Europe S.A.. In order to further analyze the sample, it is necessary to further process it. This is typically done in a laboratory to which the sample is transported after having been obtained from an animal.
  • WO 99/12475 discloses a sample capsule of an ear tag which contains unspecified reagents for further processing of the sample.
  • EP 1 088 212 discloses an ear tag which comprises a sample receiving container in which material for inactivating a protein part of a tissue sample is contained.
  • material for inactivating the protein part of a tissue sample the following are mentioned: proteinase K, a strongly alkaline solution, a molecular sieve and other components supporting an inactivation of the protein part in a sample.
  • the tissue sample is contained in the tissue sample receiving container where its protein part is inactivated.
  • the sample is transported to a laboratory where the actual analysis of the sample takes place.
  • the procedure as disclosed in the prior art is laborious and time-consuming. It requires multiple work-up steps in the laboratory and eventually may lead to a total loss of the sample.
  • the present invention has been made to improve the process according to the prior art. Ac- cordingly, it was an object of the present invention to provide for a methodology allowing a faster processing of the tissue samples. It was furthermore an object of the present invention to provide a methodology that allows to store the tissue sample for longer periods of time whilst, at the same time, being able to perform a swift analysis of the sample in terms of particular genetic trades, its genotype, the presence or absence of certain pathogens, such as BVDV.
  • an aqueous composition for dissolving biomolecules selected from nucleic acids, preferably DNA, and proteins, from a tissue sample of an animal and for subsequent
  • tissue sample - immediately after sampling, exposing said tissue sample to an aqueous composition by contacting said sample with said composition for a defined period of time, said composition comprising
  • a buffer capable of buffering at a pH range from 7 to 9 at 25°C, optionally including a pH- setting agent, such as an acidifying agent or alkalizing agent,
  • tissue of an animal is sampled using a tissue sampling tag, preferably ear tag, or a tissue sampling biopsy needle, and wherein said sample is contacted with said composition by introducing said sample into said composition, and wherein by exposing said sample to said composition, biomolecules selected from nucleic acids and proteins, from said tissue sample become dissolved in said aqueous composition to produce a biomolecule solution,
  • biomolecule solution for preserving said biomolecules or for further processing said biomolecules, such as detection of pathogen(s), e. g. BVDV, or genotyping, sequencing, hybridization analysis, or quantitative real-time PCR, or using said biomolecule solution for the detection of marker proteins, or marker nucleic acids, drugs, hormones or metabolites,
  • said aqueous composition is contained in a suitable container, such container preferably forming part of said tissue sampling tag or said tissue sampling biopsy nee- die prior to tissue sampling, wherein such container is, however, a detachable part of said tissue sampling tag or said tissue sampling biopsy needle and, after tissue sampling, may and/or will be detached therefrom.
  • said step of exposing occurs within a time period of 0.1 s to 10 s after sampling, preferably 0.1 s to 5 s after sampling.
  • said aqueous composition also comprises an alkalizing agent, such as an alkali hydroxide, more preferably NaOH or OH.
  • an alkalizing agent such as an alkali hydroxide, more preferably NaOH or OH.
  • said salt is NaCl which is present at a concentration of 1M to 2M, preferably 1M to 1.5M, more preferably 1 ,3M to 1.5M, even more preferably 1.4M.
  • said aqueous composition does not contain a proteinase K, preferably no proteinase at all.
  • said detergent in said composition is N-lauroylsarcosine, preferably N- lauroylsarcosine sodium salt.
  • said buffer is Tris and/or said chelating agent is EDTA, preferably EDTA disodium dihydrate.
  • said aqueous composition comprises, preferably consists of the following components:
  • NaCl 1-3 M preferably 1-2 M, more preferably 1-1.5 M, more preferably 1.3-1.5 M,
  • said aqueous composition comprises, preferably consists of the following components:
  • NaCl 1.35-1.45 M preferably 1.38-1.42 M
  • said biomolecule solution is used for further processing of said biomole- cules, wherein said further processing is a detection of BVDV in said biomolecule solution and thus in said tissue sample, wherein, preferably, said detection of BVD is done via nucleic acid amplification and detection of said amplified nucleic acids or via antibody-based de- tection of BVDV -proteins, such as ELIS A of BVDV-proteins.
  • the objects of the present invention are also solved by a system for preparing a tissue sample of an animal for subsequent
  • said system comprising a tissue sampling tag, preferably tissue sampling ear tag, or a tissue sampling biopsy needle, and an aqueous composition for dissolving biomolecules from a tissue sample of an animal, said composition being contained in container, said composition being as defined above.
  • said aqueous composition is contained in a suitable container, such container preferably forming part of said tissue sampling tag or said tissue sampling biopsy needle prior to tissue sampling, wherein such container is, however, a detachable part of said tis- sue sampling tag or said tissue sampling biopsy needle and, after tissue sampling, may and/or will be detached therefrom.
  • system for preparing a tissue sample of an animal is meant to refer to a combination of products which are operably linked with each other.
  • the products that are included in such system are a tissue sampling tag, preferably a tissue sampling ear tag, or, instead of the tissue sampling tag, a tissue sampling biopsy needle, and, operably linked therewith, an aqueous composition for dissolving biomolecules from a tissue sample in accordance with the present invention.
  • operably linked may refer to a physical connection between the tissue sampling tag or tissue sampling biopsy needle, on the one hand, and the aqueous composition on the other hand, or it may refer to an arrangement, wherein the aqueous composition in accordance with the present invention is provided such that, after sampling of a tissue sample, such tissue sample may be immediately contacted with the aqueous composition in accordance with the present invention, without such composition being in physical contact with the tissue sampling tag or parts thereof.
  • said aqueous composition may be contained in a suitable container, such container preferably forming part of the tissue sampling tag or of the tissue sampling biopsy needle or of the system prior to tissue sampling, wherein such container is, however, a detachable part of said tissue sampling tag or said tissue sampling biopsy needle or said system and, after tissue sampling, may and/or will be detached therefrom.
  • a suitable container such container preferably forming part of the tissue sampling tag or of the tissue sampling biopsy needle or of the system prior to tissue sampling, wherein such container is, however, a detachable part of said tissue sampling tag or said tissue sampling biopsy needle or said system and, after tissue sampling, may and/or will be detached therefrom.
  • the term "to contact with”, as used herein in the context of contacting the sample with the composition may refer to an activity whereby the tissue sample is brought into physical connection with the aqueous composition. Such activity may be rinsing, soaking, imbibing, submersing, bathing, dunking, dipping or fully or partially covering the tissue sample with said
  • tissue sampling tag refers to a device which is capable of providing an ani- mal with a tag or mark (that remains with, in, on or attached in any other way to the animal) whilst concurrently therewith obtaining a tissue sample from the animal for subsequent use.
  • a "tissue sampling unit” or, synonymously, a “tissue sampling biopsy needle”, as used herein, is meant to refer to an instrument by which, for example through a scraping, punching, tearing or other action, a tissue sample can be obtained from an animal, without, however, attaching a tag or mark, such as a tag made from plastic, metal or wood, to said animal.
  • the objects of the present invention are also solved by a method of using an aqueous composition for dissolving biomolecules selected from nucleic acids, preferably DNA, and proteins, from a tissue sample of an animal and for subsequent
  • tissue sample a tissue of an animal to produce a tissue sample of said animal and - immediately after sampling, exposing said tissue sample to an aqueous composition by contacting said sample with said composition for a defined period of time, said composition comprising
  • a buffer capable of buffering at a pH range from 7 to 9 at 25°C, optionally including a pH- setting agent, such as an acidifying agent or an alkalizing agent.
  • a pH- setting agent such as an acidifying agent or an alkalizing agent.
  • tissue of an animal is sampled using a tissue sampling tag, preferably ear tag, or a tissue sampling biopsy needle, and wherein said sample is contacted with said aqueous composition by introducing said sample into said composition, and wherein by exposing said sample to said aqueous composition, biomolecules selected from nucleic acids and proteins from said tissue sample become dissolved in said aqueous composition to produce a biomolecule solution,
  • biomolecule solution for preserving said biomolecules or for further processing said biomolecules, such as detection of pathogen(s), e. g. BVDV, or genotyping, sequencing, hybridization analysis, or quantitative real-time PCR, or using said biomolecule solution for the detection of marker proteins, or marker nucleic acids, drugs, hormones or metabolites,
  • aqueous composition optionally using said aqueous composition to store said tissue sample for later use.
  • said aqueous composition is contained in a suitable container, such container preferably forming part of said tissue sampling tag or said tissue sampling biopsy needle prior to tissue sampling, wherein such container is, however, a detachable part of said tissue sampling tag or said tissue sampling biopsy needle and, after tissue sampling, may and/or will be detached therefrom.
  • a suitable aqueous composition is characterized by high salt concentrations of at least 5-10 wt.% or of at least 1M, the presence of a detergent, a chelating agent and a buffer. After a tissue sample has been taken from an animal, it is immediately exposed to an aqueous composition in accordance with the present invention.
  • the term "immediately”, as used herein, is meant to refer to a period of time which ranges from 0.5 seconds to 2 minutes, preferably 0.5 seconds to 20 seconds, more preferably 0.5 seconds to 5 seconds.
  • the subsequent exposure time during which the sample is exposed to said aqueous composition may be any period from 5 min to several hours, e. g. 1, 2, 3, ... 12, ... 24, ... 48, ... 72, ... 120, ... 168, 336, 720 hours.
  • the aqueous composition in accordance with embodiments of the present invention not only assists to store and/or preserve the sample, but also to dissolve biomolecules selected from nucleic acids and proteins from such sample into the composition which can therefore be subsequently used directly without any further work- up-steps.
  • the aqueous composition comprises a buffer that is capable of buffering at a pH range from 7 to 9 at 25°C, a detergent, a salt at a concentration of at least 5-10 wt.% or of at least 1M, a chelating agent and water and, optionally, a pH-setting agent, such as an acidifying agent or an alkalizing agent.
  • concentration of said salt is in the range of from 5-10 wt.% or from 1M-3M, preferably 1-2M, more preferably 1-1.5M.
  • Suitable buffers are manifold. A good example is Tris.
  • buffer is meant to refer to the concept of a buffer as understood by a person skilled in the art. More specifically, it refers to a combination of a weak acid and its conjugate base or of a weak base and its conjugate acid, which combination, when dissolved in water is capable of keeping the pH value in a defined range. Such “buffer” may also be referred to as a “buffer system”.
  • Suitable buffers which may be used in embodiments of the present invention include, without being limited thereto, TAPS, Bicine, Tris, Tricine, TAPSO, HEPES, TES, and MOPS.
  • an aqueous composition in accordance with the present invention is capable of taking up biomolecules originating from a tissue sample of an animal, upon exposure of said tissue sample to said aqueous composition. It may be that these biomolecules are leaking out of the tissue sample due to the mechanical lysis/rupture of some cells in the tissue sample due to the tissue sampling action, such as punching, tearing or scratching, or it may be that some of the bio- molecules are released from the tissue sample due to the presence of a detergent in the aqueous composition according to the present invention.
  • biomolecules that become incorporated in the aqueous composition according to the present invention, preferably dissolved therein, may be nucleic acids, proteins or both from said tissue sample. They may also or alternatively be metabolites or foreign substances, such as drugs, that were contained in the tissue sample.
  • the "biomolecules” may be biomolecules from the animal from which the tissue sample has been taken, or they may be biomolecules stemming from a pathogen affecting the animal.
  • the biomolecules that are taken up in the aqueous composition according to the present invention are nucleic acids.
  • biomolecules are proteins.
  • biomolecules are a combination of both nucleic acids and proteins.
  • Nucleic acids are DNA, RNA, or a mixture of both.
  • a detergent of said composition different detergents may be used. Suitable examples include SDS or N-lauroylsarcosine, preferably its sodium salt.
  • chelating agents a suitable one being EDTA, preferably EDTA ⁇ 2 Na-2H 2 0. The inventors have surprisingly found that the aqueous composition allows to keep the tissue intact as far as possible for potential future use whilst at the same time facilitating further analysis work therewith in the laboratory, as the composition dissolves biomolecules originating from the sample.
  • biomolecules are present in the aqueous composition at concentrations high enough to enable a further processing of such (liquid) biomolecule solution in the aqueous composition.
  • nucleic acids and/or proteins of the animal as well as a pathogen affecting said animal, such as a virus, e.g. BVDV, may be soaked out of the tissue upon exposure of the sample to the aqueous composition. This may occur as quickly as over a period of a few minutes, i. e. when the sample is on its way during the transport from the farm to the laboratory.
  • the term "animal” is meant to refer to any livestock or farm animals, preferably cattle, sheep, pigs, horses and other suitable livestock animals.
  • the aqueous composition in accordance with embodiments of the present invention is also suitable for preserving the biomolecules dissolved therein.
  • the aqueous composition according to embodiments of the present invention serve for immediate further processing of the biomolecule(s) dissolved therein, but also for long term storage, either of the tissue sample that is being soaked therein, or of the biomolecules that have been dissolved in the aqueous composition.
  • the inventors have surprisingly found that the biomolecules dissolved in said aqueous composition can be stored for extended periods of time therein, such as several weeks to months.
  • a tissue sample may be stored in the aqueous composition according to the present invention for extended periods of time, such as several weeks to months.
  • An exemplary period of such storage of biomolecules or of a tissue sample is 1 week to 12 months, e. g. 2, 3, 4 weeks, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months.
  • the aqueous composition does not contain proteinase K, preferably no proteinase at all.
  • the inventors have surprisingly found that despite the absence of proteinase K or, even, any proteinase, it is still possible to obtain nucleic acid concentrations that are sufficiently high and pure enough for further processing, such as genotyping or the detection of pathogens, such as BVDV.
  • the salt in the aqueous composition according to embodiments of the present invention is present at high concentrations, preferably at concentrations in the range of from 1M to 3M, preferably 1M to 2M, more preferably 1-1.5M, more preferably 1.3M to 1.5M, even more preferably around 1.4M.
  • such salt is NaCl.
  • the inventors have surprisingly found that the use of high concentrations of salt in an aqueous composition in combination with a tissue sampling tag or tissue sampling biopsy needle allows a processing and, if desired, long-term storage/preservation of a tissue sample, without great difficulties.
  • the aqueous composition containing high concentrations of salt in accordance with the present invention may itself be used for further analysis once a tissue sample has been exposed thereto.
  • the presence of high concentrations of salt do not interfere with the further analysis of the biomolecules contained in such high salt aqueous composition.
  • a preferred detergent is N-lauroylsarcosine, preferably its sodium salt. N- lauroylsarcosine appears to be particularly suitable for a high concentration of salt being present in said aqueous composition.
  • a preferred buffer is Tris and a preferred chelating agent is EDTA, preferably its disodium di- hydrate.
  • the aqueous composition in accordance with the invention may be used for preserving biomolecules or tissue samples for extended periods of time, and/or for further processing of said biomolecules and/or tissue samples.
  • Such further processing may be a diagnostic test in respect of genomic DNA of a tissue sample from an animal which may involve genotyping of such tissue sample, i. e. a detection of the presence or absence of particular genetic traits.
  • genotyping may include identification of restriction fragment length polymorphisms (RFLP), random amplified polymorphic detection (RAPD) of genomic DNA, amplified fragment length polymorphism detection (AFLPD), polymerase chain reaction (PCR), DNA sequencing, allele specific oligonucleotide (ASO) probes, hybridization to nucleic acid microarrays or beads.
  • the further processing may, in some embodiments, also or alternatively include the detection of pathogens.
  • pathogens may be viruses, bacteria or eukaryotic single-celled or multicellular organisms, such as parasites. Detection of such pathogens may be via their nucleic acids or proteins thereof. Detec- tion of nucleic acids is done as already described, using appropriate nucleic acid technology, e. g. suitable amplification/detection methodology, such as hybridization experiments, realtime PCR, hybridization on a microarray or chip or bead on which appropriate nucleic acid probes are immobilized etc. Detection of proteins may occur for example via immunosorbent assays, involving appropriate antibodies. A typical example of such an immunosorbent assay is an ELISA.
  • BVDV it is possible to detect the same, by detecting its respective nucleic acid(s) or specific proteins that are typical thereof.
  • detection of the proteins of BVDV is via any protein suitable for such purpose that appears in the BVDV, e. g. a protein selected from Npor, the capsid protein, an envelope glycoprotein, such as ERNS, El or E2, non-structural proteins, such as p7, NS2, NS3, NS4A, NS4B etc.
  • the biomolecule solution in the aqueous composition according to the present invention may also be further used for the detection of other agents, such as the presence or absence of specific markers, the presence or absence of drugs previously or supposedly administered to the animal, the presence or absence of particular hormones and/or the presence or absence of metabolites in the tissue sample and hence, in the animal.
  • other agents such as the presence or absence of specific markers, the presence or absence of drugs previously or supposedly administered to the animal, the presence or absence of particular hormones and/or the presence or absence of metabolites in the tissue sample and hence, in the animal.
  • the use of said aqueous composition is for the detection of pathogens, in particular BVDV in a tissue sample of an animal.
  • detection may be performed using any suitable means on the biomolecule solution obtained from said tissue sample and performing any suitable amplification/detection methodology on it, such as hybridization experiments, quantitative real-time PCR, hybridization on a micro array or chip or bead on which appropriate nucleic acid probes are immobilized, flow cytometry, immunohistochemistry and other suitable methodologies.
  • suitable tissue sampling tags or tissue sampling units/biopsy needles are commercially available from a variety of manufactures, including the present applicant Allflex Europe S.A.
  • the aqueous composition in accordance with the present invention may be included in a suitable container, and any tissue sample obtained will be exposed to such aqueous composition in such suitable container.
  • suitable container in one embodiment, may be operably linked with the tissue sampling tag or tissue sampling biopsy needle or tissue sampling system.
  • the container may be a detachable part of said tissue sampling tag or tissue sampling biopsy needle or of a tissue sampling system, such container allowing the immediate introduction of a tissue sample, after it has been obtained/sampled, into said container, which container may then be detached or disconnected or released or removed from said tissue sampling tag or tissue sam- pling biopsy needle or from said system, for subsequent further processing or handling or storing of said tissue sample.
  • the tissue sample is exposed to said aqueous composition immediately after sampling as outlined above.
  • Figure 1 shows the results of an exposure of tissue samples obtained from cattle to an aqueous composition in accordance with the present invention and subsequent analysis thereof in gel electrophoresis.
  • Figure 2 shows the results of an extraction of tissue samples obtained from cattle that had been kept in an aqueous composition according to the present invention for two weeks (i. e. sample archiving) wherein the samples were then re-exposed using freshly made aqueous composition in accordance with example 1 of the present invention, and the resultant solution of this re-exposure was then analyzed.
  • Figure 2 the results of figure 2 are displayed as a photograph of a gel of the nucleic acids dissolved.
  • Figure 3 shows the results of a gel-electrophoretic separation of genomic DNA of samples stored for 12 months in a composition prepared in accordance with Example 1.
  • Example 1 Aqueous composition in accordance with embodiments of the present inven- tion
  • One liter of aqueous composition in accordance with embodiments of the present invention is produced by mixing the following: 1.576 gram TRIS
  • N-Lauroylsarcosine sodium salt MW 293,38 - 2g/l ⁇ 6.81mM
  • Example 2 Testing of aqueous composition according to example 1 with Allflex' tissue sample tag (TST) and tissue sample unit (TSU)
  • Tissue sampling tags TST
  • tissue sampling units TSU
  • TST Allflex' Tissue Sample Tag
  • TSU Tissue Sample Unit
  • Example 1 Aliquots of the composition according to the present invention (Example 1) were taken from the samples after 0, 3, 19, 24, 48, 72, 168, 336, 720 hours. To test the stability of the composition, a replenishment study was performed where five weeks in a row new aqueous composi- tion was added to 6 samples, discarding the remaining buffer in the tube.
  • the aqueous composition of the present invention can be used for downstream applications. This makes the system greatly applicable for direct genetic trait and disease testing.
  • Example 3 Nucleic acid extraction, archiving and genotyping trial
  • the aqueous composition in accordance with the present invention was assessed in terms of its suitability for dissolution and/or extraction and/or preservation of nucleic acids from tissue samples.
  • tissue samples obtained using a tissue sampling unit were stored in an aqueous composition according to example 1 for a period of two weeks. Thereafter the composition was exchanged and these tissues were then re-exposed to freshly made composition according to example 1.
  • TSU tissue sampling unit
  • an aqueous composition in accordance with the present invention not only is suitable to dissolve nucleic acids from a sample immediately after sampling but also to store a tissue sample therein and subsequently use such sample for further re- exposure in fresh aqueous composition of the present invention.
  • Example 4 Long-term storage of tissue samples in aqueous composition according to the present invention
  • ear punch samples were collected from both ears of freshly slaughtered cattle, using an Allflex forceps system and an Allflex tissue sampling biopsy needle (TSU). Samples were stamped into plastic recipients filled with an aqueous composition according to Example 1. Such aqueous composition in accordance with the present invention is also sometimes referred to in this Example 4 as "Liquid D" or “preservative agent Liquid D” (see further be- low). Collection of the samples, labeling of the sample containers, and immediate shipping per courier services were carried out by Allflex. One day later, the samples reached the Laboratory in optically assured condition. Upon receipt, these samples were sorted as reflected by the sample labeling and information in Table 1 and were stored in darkness in the aqueous composition of Example 1.
  • Table 1 Overview of sample labeling and of sample storage. As Table 1 reflects, the first round of preparation and examination of 5 samples was processed the day after receipt of the samples (Time-Table "0-Months"), all subsequent examinations occurred after 3 -months intervals (Time-Table "3, 6, 9, and 12 Months").
  • Variant 1 made use of whole ear punch samples
  • Variant 2 was based on a fraction of the ear punch sample (about one third of ear punch samples). This comparison appeared important, due to the imperative that processing of the samples during routine procedures has to be unfailingly continuous and reproducible. It is conceivable that the totality of the ear punch sam- pies can be implemented at once and thus processed faster, concurrently holding DNA concentration within a narrower concentration range, thereby excluding subjective effects. As opposed to that, during routine procedure used in this example, only a fraction of the original probe was used so as to hold on to a backup.
  • DNA concentration for Quantity Variant 1 using whole ear punch samples ranged from 191— 829 ng/ ⁇ (data not shown) and for Quantity Variant 2 using about 1/3 of ear punch samples ranged from 55 - 323 ng/ ⁇ . This shows significantly higher yield in DNA using all samples but also a higher spreading of measurement values. Therefore it was decided to use only a sample fraction (1/3) for all further analyses.
  • Tables 3 to 6 show the corresponding data after 3, 6, 9, and 12 months of storage of the tissue samples. Each sample generated a sufficient quantity of genomic DNA. Concentration of DNA showed the following ranges: 59 - 213 ng/ ⁇ (3 months), 204 - 663 ng/ ⁇ (6 months), 98 - 524 ng/ ⁇ (9 months), and 70 - 654 ng/ ⁇ (12 months) respectively.
  • the samples obtained, after 0. 3, 6, 9 and 12 months were processed (i.e. lysed) as described above, and were gel-electrophoretically separated and analyzed. Exemplary results of such gel-electrophoretic analysis are shown in figure 3 which shows the gel-electrophoretic separation of genomic DNA for samples that had been stored for 12 months in an aqueous composition of the present invention. It becomes clear that these samples show a clearly observable high-molecular DNA band, indicating genomic DNA which leads to the conclusion that sam- pies storage in any of the tested storage variants yielded very good DNA quality for subsequent molecular-genetic diagnostics even after a storage length of 12 months.
  • the aqueous composition according to the present invention is also suitable for long term storage of tissue samples, which can then be used, after storage, for subsequent further processing and analysis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/EP2017/056782 2016-03-24 2017-03-22 Use of an aqueous composition for dissolving biomolecules from a tissue sample Ceased WO2017162721A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP17711678.7A EP3417060B8 (en) 2016-03-24 2017-03-22 Use of an aqueous composition for dissolving biomolecules from a tissue sample
RU2018133641A RU2745529C2 (ru) 2016-03-24 2017-03-22 Применение водной композиции для растворения биомолекул из образца ткани
CA3017679A CA3017679A1 (en) 2016-03-24 2017-03-22 Use of an aqueous composition for dissolving biomolecules from a tissue sample
AU2017237464A AU2017237464B2 (en) 2016-03-24 2017-03-22 Use of an aqueous composition for dissolving biomolecules from a tissue sample
BR112018069110-0A BR112018069110B1 (pt) 2016-03-24 2017-03-22 Uso de uma composição aquosa para dissolução de biomoléculas de uma amostra de tecido
CN201780031557.3A CN109153991B (zh) 2016-03-24 2017-03-22 水性组合物用于溶解组织样本中生物分子的用途
JP2019501754A JP2019512274A (ja) 2016-03-24 2017-03-22 組織試料由来の生体分子を溶解させるための水性組成物の使用
PL17711678T PL3417060T3 (pl) 2016-03-24 2017-03-22 Zastosowanie wodnej kompozycji do rozpuszczania biocząsteczek z próbki tkanki
US16/086,908 US20190100746A1 (en) 2016-03-24 2017-03-22 Use of an aqueous composition for dissolving biomolecules from a tissue sample

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16162349.1 2016-03-24
EP16162349.1A EP3222719B8 (en) 2016-03-24 2016-03-24 Use of an aqueous composition for dissolving biomolecules from a tissue sample

Publications (1)

Publication Number Publication Date
WO2017162721A1 true WO2017162721A1 (en) 2017-09-28

Family

ID=55646357

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/056782 Ceased WO2017162721A1 (en) 2016-03-24 2017-03-22 Use of an aqueous composition for dissolving biomolecules from a tissue sample

Country Status (13)

Country Link
US (1) US20190100746A1 (enExample)
EP (2) EP3222719B8 (enExample)
JP (1) JP2019512274A (enExample)
CN (1) CN109153991B (enExample)
AR (1) AR108041A1 (enExample)
AU (1) AU2017237464B2 (enExample)
CA (1) CA3017679A1 (enExample)
DK (1) DK3222719T3 (enExample)
ES (1) ES2802453T3 (enExample)
PL (2) PL3222719T3 (enExample)
RU (1) RU2745529C2 (enExample)
UY (1) UY37165A (enExample)
WO (1) WO2017162721A1 (enExample)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012475A1 (de) 1997-09-11 1999-03-18 Biopsytec Gmbh Verfahren und vorrichtung zur entnahme von biologischen proben
EP1088212A1 (de) 1998-05-25 2001-04-04 Agrobiogen GmbH Vorrichtung und verfahren zur gewinnung und erst-aufbereitung von gewebeproben für die molekulargenetische diagnostik
WO2009085355A2 (en) * 2007-10-01 2009-07-09 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
WO2012054613A2 (en) * 2010-10-20 2012-04-26 Bio-Rad Laboratories, Inc. Stabilized protease-containing solutions
WO2016029020A1 (en) * 2014-08-20 2016-02-25 Abogen, Inc. Devices, solutions and methods for sample collection related applications

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700555A (en) * 1970-10-12 1972-10-24 Technicon Instr Method and apparatus for lymphocyte separation from blood
JP3678752B2 (ja) * 1994-10-31 2005-08-03 ボストン・サイエンティフィック・コーポレーション バイオプシー針
JP2004533805A (ja) * 2000-10-18 2004-11-11 フアーマセツト・リミテツド 疾患細胞中の核酸の多重定量
US7473532B2 (en) * 2003-03-10 2009-01-06 Expression Pathology, Inc. Liquid tissue preparation from histopathologically processed biological samples, tissues and cells
AU2005209901A1 (en) * 2004-01-30 2005-08-18 The Texas A & M University System Compositions, methods and uses for a novel family of peptides
FR2917574B1 (fr) * 2007-06-22 2010-05-07 Chevillot Sarl Boucle auriculaire de marquage avec dispositif de prelevement de tissus
CA2707841C (en) * 2007-12-04 2017-10-24 Prionics Ag Kit and method for detecting bovine viral diarrhea virus in tissue samples
WO2009143499A1 (en) * 2008-05-23 2009-11-26 Life Technologies Corporation Methods and kits for extraction of dna
BR112012004699B1 (pt) * 2009-09-03 2019-10-15 Becton, Dickinson And Company Métodos, composições e kits para lise química direta
RU2422532C2 (ru) * 2009-09-18 2011-06-27 Общество с ограниченной ответственностью "РусИнкор-Мед" Способ выделения низкомолекулярных ядерных рибонуклеопротеидов (рнп) из тканей и органов млекопитающих
WO2011091438A1 (en) * 2010-01-25 2011-07-28 George Mason Intellectual Properties, Inc. Improved one-step cell and tissue preservative for morphologic and molecular analysis
EP2739752B1 (en) * 2011-08-03 2017-07-19 Bio-Rad Laboratories, Inc. Filtering small nucleic acids using permeabilized cells
WO2013036875A1 (en) * 2011-09-07 2013-03-14 Mount Sinai School Of Medicine Ceramidase and cell differentiation
AU2013240200B2 (en) * 2012-03-28 2016-10-20 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for the collection and isolation of nucleic acids from biological specimens
WO2014049619A1 (en) * 2012-09-28 2014-04-03 Bose Institute Cancer chemotherapeutic agent/formulation, manufacture and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012475A1 (de) 1997-09-11 1999-03-18 Biopsytec Gmbh Verfahren und vorrichtung zur entnahme von biologischen proben
EP1088212A1 (de) 1998-05-25 2001-04-04 Agrobiogen GmbH Vorrichtung und verfahren zur gewinnung und erst-aufbereitung von gewebeproben für die molekulargenetische diagnostik
WO2009085355A2 (en) * 2007-10-01 2009-07-09 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
WO2012054613A2 (en) * 2010-10-20 2012-04-26 Bio-Rad Laboratories, Inc. Stabilized protease-containing solutions
WO2016029020A1 (en) * 2014-08-20 2016-02-25 Abogen, Inc. Devices, solutions and methods for sample collection related applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAY ET AL: "Standard Operating Procedure Tissue sample collection and storage for mammals", 1 December 2015 (2015-12-01), XP055304780, Retrieved from the Internet <URL:https://www.dpaw.wa.gov.au/images/documents/plants-animals/monitoring/sop/sop08.4_tissuesample_v1.0.pdf> [retrieved on 20160922] *
MICHAEL A. GRAY ET AL: "Comparison of DNA preservation methods for environmental bacterial community samples", FEMS MICROBIOLOGY ECOLOGY., vol. 83, no. 2, 8 October 2012 (2012-10-08), NL, pages 468 - 477, XP055304779, ISSN: 0168-6496, DOI: 10.1111/1574-6941.12008 *

Also Published As

Publication number Publication date
CN109153991A (zh) 2019-01-04
RU2745529C2 (ru) 2021-03-26
CA3017679A1 (en) 2017-09-28
EP3417060B8 (en) 2021-03-17
PL3222719T3 (pl) 2020-09-21
EP3222719A1 (en) 2017-09-27
US20190100746A1 (en) 2019-04-04
JP2019512274A (ja) 2019-05-16
ES2802453T3 (es) 2021-01-19
UY37165A (es) 2017-05-31
EP3222719B1 (en) 2020-04-22
EP3417060B1 (en) 2020-12-30
BR112018069110A2 (pt) 2019-01-22
AR108041A1 (es) 2018-07-11
DK3222719T3 (da) 2020-05-11
RU2018133641A (ru) 2020-03-24
EP3417060A1 (en) 2018-12-26
AU2017237464B2 (en) 2023-07-27
AU2017237464A1 (en) 2018-10-04
CN109153991B (zh) 2022-06-17
EP3222719B8 (en) 2021-03-17
PL3417060T3 (pl) 2021-07-19
RU2018133641A3 (enExample) 2020-05-29

Similar Documents

Publication Publication Date Title
CN109971749A (zh) 用于从生物样品中采集和分离核酸的组合物和方法
JP6254117B2 (ja) 制御された移転生体試料採取装置およびその装置を使用する方法
CN101443456B (zh) 纯化方法和试剂盒
US10150118B2 (en) Controlled transfer biological sample collection devices and methods of using such devices
JPWO2010064634A1 (ja) 糞便試料の調製方法、糞便試料調製用溶液、及び採便用キット
JPWO2017104132A1 (ja) 採便器、便検体中の成分の測定方法、便検体中の成分の安定化方法、及び、便検体の保存方法
Altamiranda et al. Clinical and reproductive consequences of using BVDV-contaminated semen in artificial insemination in a beef herd in Argentina
CN108384859A (zh) 与脂尾型绵羊的尾型性状相关的snp标记及应用
JP2008249543A (ja) 組織標本からの細胞の調製方法
Nieves‐Colón et al. Ancient DNA analysis of archaeological remains
EP3222719B1 (en) Use of an aqueous composition for dissolving biomolecules from a tissue sample
ES2326341T3 (es) Metodo para el aislamiento de arnm a partir de tejido fijado con formalina, embebido en parafina.
BR112018069110B1 (pt) Uso de uma composição aquosa para dissolução de biomoléculas de uma amostra de tecido
JPWO2010134245A1 (ja) 哺乳細胞由来核酸の回収方法、核酸解析方法、及び採便用キット
Karabulut et al. Sperm selection with Annexin-V coated polystrene bead technique (APB-Tech): A novel and reliable method for the microscopic selection of viable and non-apoptotic sperm to be used for intracytoplasmic sperm injection
JP2019512274A5 (enExample)
Lopes et al. In situ Hybridization of miRNAs in Human Embryonic Kidney and Human Pluripotent Stem Cell-derived Kidney Organoids
Rutherford Schistosomiasis, ancient and modern: the application of scientific techniques to diagnose the disease
Kampa et al. Reproductive Loss due to pestivirus infection in dairy cattle herds in Thailand
Crockford White spot disease
DK2784512T3 (en) PROCEDURE FOR PREDICTING THE FERTILITY OF A BULL BASED ON ITS EJACULATE
Franz et al. Oesophagoscopy and detection of viral nucleic acids in oesophageal biopsies–A contribution to BVDV diagnosis
Pawar et al. Prevalence of Haemoprotozoan Infection in Equines of Maharashtra.
Cepica et al. Field evaluation of CIEP and PCR detection/removal control methods of Aleutian mink disease (AD) in Canada
RÎMBU et al. VIROLOGICAL SUPERVISION OF BLUETONGUE DISEASE IN THE SOUTH-EAST REGION OF ROMANIA.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3017679

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2017711678

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2019501754

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017711678

Country of ref document: EP

Effective date: 20180919

ENP Entry into the national phase

Ref document number: 2017237464

Country of ref document: AU

Date of ref document: 20170322

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018069110

Country of ref document: BR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17711678

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 112018069110

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180920